Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 13/20 | 0.79 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.69 |
| ▸ | FYN | P06241 | 4/20 | 0.61 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL980269 | 0.84 | GABRA1 (0.63) | CHEK2GABRA1GABRB2 | |
| SCHEMBL1679446 | 0.81 | PRKD3 (0.68) | CHEK2CHEK1FYNMAP4K4GABRA1 | |
| SCHEMBL4620367 | 0.80 | FYN (0.76) | CHEK2CHEK1FYNMKNK1MAP4K4 | |
| SCHEMBL4621282 | 0.80 | FYN (0.70) | CHEK2CHEK1FYNMKNK1MAP4K4 | |
| SCHEMBL13968138 | 0.79 | FYN (0.69) | CHEK2CHEK1FYNMKNK1MAP4K4 | |
| SCHEMBL13977197 | 0.79 | CHEK2 (0.66) | CHEK2CHEK1FYNMKNK1MAP4K4 | |
| SCHEMBL1679739 | 0.77 | FYN (0.81) | CHEK2CHEK1FYNMKNK1 | |
| SCHEMBL1679160 | 0.77 | FYN (0.63) | CHEK2CHEK1FYNMKNK1MAP4K4 | |
| SCHEMBL15451325 | 0.76 | TSHR (0.68) | CHEK2CHEK1GABRA1GABRB2 | |
| SCHEMBL2224294 | 0.76 | FYN (0.72) | CHEK2CHEK1FYNMKNK1MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | claimed |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| WO-2008074997-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | PKD2, PKD1, BAZ2B | CHEK2 587/4885CHEK1 805/4885FYN 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.